<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2511211369
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Polivy
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        POLATUZUMAB VEDOTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        140
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        52669.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BSP PHARMACEUTICALS S.r.l." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BSP PHARMACEUTICALS S.r.l.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3402]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Roche Products Saudi Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            F.Hoffmann-La Roche Ltd. 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.</p><p>&nbsp;</p><p><strong>What Polivy is</strong></p><p>Polivy is a cancer medicine that contains the active substance polatuzumab vedotin.</p><p>&nbsp;</p><p><strong>What Polivy is used for</strong></p><p>Polivy is given to treat &ldquo;diffuse large B-cell lymphoma&rdquo; that has come back or has not got better with at least one previous therapy and when you cannot receive a stem cell transplant.</p><p>Diffuse large B-cell lymphoma is a cancer that develops from B lymphocytes also called B-cells. These are a type of blood cells.</p><p>&nbsp;</p><p><strong>How Polivy works</strong></p><p>The active substance in Polivy is made up of a monoclonal antibody linked to Mono-Methyl Auristatin E (MMAE), a substance that can kill cancer cells. The monoclonal antibody part of the medicine attaches to a target on B cells. Once attached to B cells, the medicine releases MMAE into the B cells and kills them.</p><p><strong>&nbsp;</strong></p><p><strong>What other medicines Polivy is given with</strong></p><p>Polivy is given in combination with two other cancer medicines called rituximab and bendamustine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Polivy</strong></p><ul><li>if you are allergic to polatuzumab vedotin or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>If you are not sure, talk to your doctor or nurse before you are given Polivy.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or nurse before you are given Polivy if any of the following apply to you (or you are not sure):</p><ul><li>&nbsp;you have ever had brain or nerve problems such as:<ul><li>memory problems</li><li>difficulty moving or sensations in your body such as feeling pins and needles, burning, pain and discomfort even from slight touch</li><li>eyesight problems</li></ul></li><li>&nbsp;you have ever had liver problems</li><li>you think you have an infection or have had long-lasting or repeated infections such as herpes (see &ldquo;Infections&rdquo; in section 4).</li><li>you are due to have a vaccine or you know you may need to have one in the near future</li></ul><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure) talk to your doctor or nurse before you are given Polivy.</p><p>&nbsp;</p><p><strong>Pay attention to the following side effects</strong></p><p>Polivy can cause some serious side effects that you need to tell your doctor or nurse about straight away. These include:</p><p>&nbsp;</p><p><strong>Myelosuppression</strong></p><p>Myelosuppression is a condition in which the production of blood cells is decreased, resulting in fewer red blood cells, white blood cells, and platelets. Your doctor will do blood tests to check your blood cell count.</p><p>Tell your doctor or nurse straight away if you:</p><ul><li>develop chills or shivering</li><li>have a fever</li><li>have headaches</li><li>feel tired</li><li>feel dizzy</li><li>look pale</li></ul><p>have unusual bleeding, bruising under the skin, bleeding longer than usual after your blood has been drawn, or bleeding from your gums.</p><p>&nbsp;</p><p><strong>Peripheral neuropathy</strong></p><p>Tell your doctor or nurse straight away if you have any problems with a change in the sensitivity of your skin, especially in your hands or feet, such as:</p><ul><li>numbness</li><li>tingling</li><li>a burning sensation</li><li>pain</li><li>discomfort or weakness.</li></ul><p>&nbsp;</p><p>If you had any of these symptoms before treatment with Polivy, tell your doctor straight away if you notice any changes in them.</p><p>If you have symptoms of peripheral neuropathy, your doctor may lower your dose.</p><p>&nbsp;</p><p><strong>Infections</strong></p><p>Signs and symptoms of infections vary between individuals, tell your doctor or nurse straight away if you develop symptoms of an infection such as:</p><ul><li>fever</li><li>cough</li><li>chest pain</li><li>tiredness</li><li>painful rash</li><li>sore throat</li><li>burning pain when passing urine</li><li>feeling weak or generally unwell.</li></ul><p>&nbsp;</p><p><strong>Progressive multifocal leukoencephalopathy (PML)</strong></p><p>PML is a very rare and life threatening infection in the brain, that has occured in one patient treated with Polivy together with bendamustine and another medicine called obinutuzumab.</p><p>Tell your doctor or nurse straight away if you have:</p><ul><li>memory loss</li><li>trouble speaking</li><li>difficulty walking</li><li>problems with your eyesight.</li></ul><p>If you had any of these symptoms before treatment with Polivy, tell your doctor straight away if you notice any changes in them. You may need medical treatment.</p><p>&nbsp;</p><p><strong>Tumour lysis syndrome </strong></p><p>Some people may develop unusual levels of some substances (such as potassium and uric acid) in the blood caused by the fast breakdown of cancer cells during treatment. This is called tumour lysis syndrome. Your doctor, pharmacist or nurse will do blood tests to check for the condition.</p><p>&nbsp;</p><p><strong>Infusion-related reactions</strong></p><p>Infusion-related reactions, allergic or anaphylactic (more severe allergic) reactions can happen. Your doctor or nurse will check for side effects during your infusion and for 30 to 90 minutes afterwards. If you get any serious reaction, your doctor may stop treatment with Polivy.</p><p>&nbsp;</p><p><strong>Liver damage</strong></p><p>This medicine can cause inflammation or damage to cells in the liver that affect the normal function of the liver. Injured liver cells may leak high amounts of certain substances (liver enzymes and bilirubin) into the bloodstream, in which can be detected by blood tests.</p><p>In most cases you will not have any symptoms but tell your doctor or nurse straight away if you get:</p><ul><li>yellowing of your skin and of the whites of your eyes (jaundice).</li></ul><p>Your doctor will check your blood to test your liver function before and regularly during treatment.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>This medicine should not be used in children or young people under the age of 18. This is because there is no information about its use in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Polivy</strong></p><p>Tell your doctor or nurse if you are taking, have recently taken or might start taking any other</p><p>medicines. This includes medicines obtained without a prescription and herbal medicines.</p><p><strong>&nbsp;</strong></p><p><strong>Contraception (women and men) </strong></p><p>If you are a woman of childbearing age, you must use effective contraception during treatment and for 9 months after the last dose of Polivy.</p><p>Men must use contraception during treatment and for 6 months after the last dose of Polivy.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy </strong></p><p>It is important to tell your doctor before and during treatment if you are pregnant, think you may be</p><p>pregnant, or are planning to get pregnant. This is because Polivy can affect your baby&rsquo;s health. You should not use this medicine if you are pregnant unless you and your doctor decide that the</p><p>benefit to you outweighs possible risk to the unborn baby.</p><p>&nbsp;</p><p><strong>Breast-feeding </strong></p><p>Do not breast-feed while receiving Polivy because small amount of Polivy may pass into your breast milk.</p><p>&nbsp;</p><p><strong>Fertility </strong></p><p>Men being treated with this medicine are advised to have sperm samples preserved and stored before treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Polivy has a minor influence on your ability to drive, cycle or use any tools or machines. If you get infusion-related reactions or nerve damage, or if you feel tired, weak or dizzy (see section 4) do not drive, cycle or use tools or machines until the reaction stops.</p><p>See section 4 for more information about side effects.</p><p>&nbsp;</p><p><strong>Polivy contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How Polivy is given</strong></p><p>Polivy is given under the supervision of a doctor experienced in giving such treatments. It is given into a vein, as a drip over 90 minutes.</p><p>&nbsp;</p><p><strong>How much Polivy is given </strong></p><p>The dose of this medicine depends on your body weight.</p><ul><li>The usual starting dose is 1.8 mg for each kilogram of your body weight.</li><li>If you have peripheral neuropathy, your doctor may lower your dose to 1.4 mg for each kilogram of your body weight.</li></ul><p>You will be given 6 treatment cycles of Polivy in combination with two other medicines called rituximab and bendamustine.</p><p>Each cycle lasts 21 days.</p><p>&nbsp;</p><p><strong>If you miss a dose of Polivy</strong></p><p>If you miss an appointment, make another one straight away. For the treatment to be fully effective, it is very important not to miss a dose.</p><p>&nbsp;</p><p><strong>If you stop receiving Polivy</strong></p><p>Do not stop treatment with Polivy unless you have discussed this with your doctor. This is because stopping treatment may make your condition worse.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects have been reported with this medicine:</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>Tell your doctor or nurse straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment. These may be new symptoms or a change in your current symptoms.</p><ul><li>fevers and chills</li><li>rash/hives</li><li>severe infections</li><li>pneumonia (lung infection)</li><li>herpes infection</li><li>viral infections</li><li>unusual bleeding or bruising under the skin</li><li>memory loss, trouble speaking, difficulty walking or problems with your eyesight</li><li>yellowing of skin or whites of your eyes</li></ul><p><strong>&nbsp;</strong></p><p><strong>Other side effects</strong></p><p>Tell your doctor or nurse if you notice any of the following side effects:</p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><ul><li>fever or chills</li><li>cough</li><li>vomitting</li><li>pneumonia (lung infection)</li><li>diarrhoea or constipation</li><li>feeling sick (nausea)</li><li>abdominal (belly) pain</li><li>feeling tired (anaemia)</li><li>not feeling hungry</li><li>itchiness</li><li>loss of weight</li><li>infusion-related reactions</li><li>common cold</li><li>herpes infection</li><li>dizziness</li><li>unusual sensations</li></ul><p>&nbsp;</p><p><strong>Common </strong></p><ul><li>severe infections</li><li>viral infections</li><li>problems walking</li><li>inflammation of the lungs</li><li>raised liver enzymes</li><li>joint pain</li></ul><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Polivy will be stored by the healthcare professionals at the hospital or clinic. The storage details are as follows</p><ul><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. The expiry date refers to the last day of that month.</li><li>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</li><li>Do not freeze.</li><li>Keep the container in the outer carton in order to protect from light.</li></ul><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is polatuzumab vedotin. Each vial contains 140 milligrams (mg) polatuzumab vedotin. After reconstitution each millilitre (mL) contains 20 mg polatuzumab vedotin.</li></ul><p>&nbsp;</p><ul><li>The other ingredients are: succinic acid, sodium hydroxide, sucrose, polysorbate 20. See section &ldquo;Polivy contains sodium&rdquo;.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Polivy powder for concentrate for solution for infusion is a white to slightly greyish-white cake provided in a glass vial.
	
	Each pack of Polivy consists of one vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>F. Hoffmann-La Roche Ltd,</p><p>Grenzacherstrasse 124</p><p>CH-4070 Basel</p><p>Switzerland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in January 2020

To report any side effect(s):
Saudi Arabia:
- The National Pharmacovigilance and Drug Safety Centre (NPC)
o	Fax: +966-11-205-7662
o	Call NPC at +966-11-2038222, Exts: 2317-2356-2340.
o	SFDA call center: 19999
o	E-mail: npc.drug@sfda.gov.sa
o	Website: www.sfda.gov.sa/npc
	
	
Other GCC States:
-Please contact the relevant competent authority.
	
	
Council of Arab Health Ministers
	
This is a Medicament
- Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
- Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
- The doctor and the pharmacist are the experts in medicines, their benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed for you.
- Do not repeat the same prescription without consulting your doctor.
- Keep all medicaments out of reach of children.
	
	Council of Arab Health Ministers
	Union of Arab Pharmacists
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يخضع هذا الدواء للمراقبة الإضافية. وهذا سوف يسمح لكم بالتعرف السريع على معلومات السلامة الجديدة. ويمكنك المساعدة من خلال تسجيل أية آثار جانبية قد تحدث لك. انظر نهاية القسم الرابع للتعرف على كيفية تسجيل الآثار الجانبية.</p><p dir="RTL"><strong>ما هو دواء بوليفي</strong></p><p dir="RTL">دواء بوليفي هو دواء للسرطان يحتوي على المادة الفعالة بولاتوزوماب فيدوتين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيم يستخدم دواء بوليفي</strong></p><p dir="RTL">يستخدم دواء بوليفي لعلاج &quot;سرطان اللمفومات المنتشرة البائية الخلايا&quot; التي عادت أو لم تتحسن مع علاج سابق واحد على الأقل وعندما لا تتمكن من إجراء عملية زرع خلايا جذعية.</p><p dir="RTL">سرطان اللمفومات المنتشرة البائية الخلايا هو سرطان يتطور من الخلايا الليمفاوية وتسمى أيضا اللمفومات بائية الخلايا. وهي نوع من خلايا الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل دواء بوليفي</strong></p><p dir="RTL">تتكون المادة الفعالة في دواء بوليفي من جسم مضاد أحادي النسيلة مرتبط بأحادي مثيل أوريستاتين إي، وهي مادة يمكن أن تقتل الخلايا السرطانية. يعلق جزء من الجسم المضاد الوحيد النسيلة من الدواء على هدف على الخلايا البائية. بمجرد إرفاقه بالخلايا البائية، يقوم الدواء بإطلاق أحادي مثيل أوريستاتين إي للخلايا البائية ويقتلها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي الأدوية الأخرى التي تعطى معها دواء بوليفي</strong></p><p dir="RTL">يعطى دواء بوليفي مع اثنين من أدوية السرطان الأخرى تسمى ريتوكسيماب وبنداموستين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم دواء بوليفي في الحالات الآتية:</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية تجاه بولاتوزوماب فيدوتين أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</li></ul><p dir="RTL">إذا لم تكن متأكدًا، يرجى التحدث إلى طبيبك أو ممرضتك قبل أن تحصل على دواء بوليفي.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">يرجى التحدث إلى طبيبك أو ممرضتك قبل تلقي دواء بوليفي إذا كان أي مما يلي ينطبق عليك (أو لم تكن متأكدًا):</p><ul dir="rtl"><li>سبق أن عانيت من مشاكل في الدماغ أو الأعصاب مثل:<ul><li>مشاكل الذاكرة</li><li>صعوبة في الحركة أو الإحساس في جسمك مثل الشعور بالوجع والإبر والحرقة والألم وعدم الراحة حتى من لمسة خفيفة</li><li>مشاكل في الرؤية</li></ul></li><li>إن كنت تعاني من مشاكل في الكبد</li><li>إن كنت تعتقد أنك مصاب أو تعاني من عدوى طويلة الأمد أو متكررة مثل الهربس (انظر &quot;الالتهابات&quot; في القسم 4).</li><li>من المفترض أن يكون لديك لقاح أو تعرف أنك قد تحتاج إلى الحصول على لقاح في المستقبل القريب.</li></ul><p dir="RTL">يرجى التحدث إلى طبيبك أو ممرضتك قبل تلقي دواء بوليفي إذا كان أي مما سبق ينطبق عليك (أو لم تكن متأكدًا):</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يرجى الانتباه للآثار الجانبية التالية</strong></p><p dir="RTL">يمكن أن يسبب دواء بوليفي بعض الآثار الجانبية الخطيرة التي تحتاج إلى إخبار طبيبك أو ممرضتك على الفور. وتشمل هذه:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبت نقي العظم</strong></p><p dir="RTL">كبت نقي العظم هو حالة ينخفض فيها إنتاج خلايا الدم، مما يؤدي إلى انخفاض عدد خلايا الدم الحمراء وخلايا الدم البيضاء والصفائح الدموية. سيقوم الطبيب بإجراء اختبارات دم للتحقق من عدد خلايا الدم لديك.</p><p dir="RTL">أخبر طبيبك أو الممرض على الفور إذا كنت:</p><ul dir="rtl"><li>تشعر بقشعريرة أو ارتعاش</li><li>لديك حمى</li><li>تعاني من صداع</li><li>تشعر بالتعب</li><li>تشعر بالدوار</li><li>تبدو شاحبًا</li><li>تعاني من نزيف غير عادي أو كدمات تحت الجلد أو نزيف أطول من المعتاد بعد سحب دمك أو نزيف من اللثة.</li></ul><p>&nbsp;</p><p><strong>الاعتلال العصبي المحيطي</strong></p><p dir="RTL">استشر طبيبك أو ممرضتك على الفور إذا كنت تواجه أي مشاكل مع تغير حساسية بشرتك، وخاصة في يديك أو قدميك، مثل:</p><ul dir="rtl"><li>التنميل</li><li>الوخز</li><li>الإحساس الحارق</li><li>الألم</li><li>عدم الراحة أو الضعف.</li></ul><p dir="RTL">إذا كان لديك أي من هذه الأعراض قبل العلاج بدواء بوليفي، استشر طبيبك على الفور إذا لاحظت أي تغييرات فيها.</p><p dir="RTL">إذا كان لديك أعراض الاعتلال العصبي المحيطي، فقد يخفض طبيبك الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العدوى</strong></p><p dir="RTL">تختلف علامات وأعراض العدوى بين الأفراد، أخبر طبيبك أو ممرضتك على الفور إذا ظهرت عليك أعراض العدوى مثل:</p><ul dir="rtl"><li>الحمى</li><li>السعال</li><li>ألم في الصدر</li><li>التعب</li><li>طفح مؤلم</li><li>اتهاب الحلق</li><li>ألم عند التبول</li><li>الشعور بالضعف أو التوعك بشكل عام.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اعتلال الدماغ التقدمي متعدد البؤر (</strong><strong>PML</strong><strong>)</strong>:</p><p dir="RTL">يعتبر اعتلال الدماغ التقدمي متعدد البؤر (PML) عدوى نادرة جدًا وتهدد حياة الدماغ، وقد حدثت في مريض عولج بدواء بوليفي مع بنداموستين وأدوية أخرى تسمى أوبينوتوزوماب.</p><p dir="RTL">استشر طبيبك أو ممرضتك على الفور إذا كنت تعاني من:</p><ul dir="rtl"><li>فقدان الذاكرة</li><li>صعوبة في التحدث</li><li>صعوبة في المشي</li><li>مشاكل في الرؤية.</li></ul><p dir="RTL">إذا كان لديك أي من هذه الأعراض قبل العلاج بدواء بوليفي، استشر طبيبك على الفور إذا لاحظت أي تغييرات فيها. قد تحتاج إلى علاج طبي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>متلازمة تحلل الورم</strong></p><p dir="RTL">قد يصاب بعض الأشخاص بمستويات غير عادية لبعض المواد (مثل البوتاسيوم وحمض اليوريك) في الدم الناجم عن الانهيار السريع للخلايا السرطانية أثناء العلاج. وهذا ما يسمى بمتلازمة تحلل الورم. سيقوم طبيبك أو الصيدلي أو ممرضتك بإجراء فحوصات دم للتحقق من الحالة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ردود الفعل المتعلقة بالحقن</strong></p><p dir="RTL">يمكن أن تحدث ردود الفعل المتعلقة بالحقن أو الحساسية أو الحساسية المفرطة (الحساسية الشديدة). سيتحقق طبيبك أو ممرضتك من الآثار الجانبية أثناء الحقن ولمدة 30 إلى 90 دقيقة بعد ذلك. إذا حصل أي رد فعل خطير، فقد يتوقف طبيبك عن العلاج بدواء بوليفي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تلف الكبد</strong></p><p dir="RTL">يمكن أن يسبب هذا الدواء التهابًا أو تلفًا للخلايا في الكبد والتي تؤثر على وظيفة الكبد الطبيعية. قد تسرب خلايا الكبد المصابة كميات كبيرة من مواد معينة (أنزيمات الكبد والبيليروبين) في مجرى الدم، والتي يمكن اكتشافها باختبارات الدم.</p><p dir="RTL">في معظم الحالات، لن تظهر لك أي أعراض ولكن استشر طبيبك أو ممرضتك على الفور إذا ظهر عليك:</p><ul dir="rtl"><li>اصفرار في بشرتك وبياض عينيك (اليرقان).</li></ul><p dir="RTL">سيفحص طبيبك دمك لاختبار وظائف الكبد قبل العلاج بانتظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والبالغين</strong></p><p dir="RTL">لا يستخدم هذا الدواء في الأطفال أو الشباب الذين تقل أعمارهم عن 18 عامًا لأنه لا توجد معلومات حول استخدامه في هذه الفئة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وبوليفي</strong></p><p dir="RTL">أخبر طبيبك أو ممرضك إذا كنت تتناول أو قد تناولت مؤخرًا أو قد تبدأ في تناول أي أدوية أخرى. وهذا يشمل الأدوية التي تم الحصول عليها دون وصفة طبية والأدوية العشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وسائل منع الحمل (النساء والرجال)</strong></p><p dir="RTL">إذا كنت امرأة في سن الإنجاب، فيجب عليك استخدام وسائل منع الحمل الفعالة أثناء العلاج ولمدة 9 أشهر بعد آخر جرعة من دواء بوليفي.</p><p dir="RTL">يجب أن يستخدم الرجال وسائل منع الحمل أثناء العلاج ولمدة 6 أشهر بعد آخر جرعة من دواء بوليفي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">من المهم أن تخبر طبيبك قبل وأثناء العلاج إذا كنتِ حاملاً أو تعتقدين أنكِ حاملاً أو تخططين للحمل. وذلك لأن دواء بوليفي يمكن أن يؤثر على صحة طفلك. يجب عدم استخدام هذا الدواء إذا كنتِ حاملاً إلا إذا قررت أنتِ وطبيبك أن الفائدة التي تفوقها تفوق الخطر المحتمل على الطفل الذي لم يولد بعد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">لا ترضع من الثدي أثناء تلقي دواء بوليفي لأن كمية صغيرة من دواء بوليفي قد تنتقل إلى حليب الثدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">يُنصح الرجال المعالجون بهذا الدواء بحفظ عينات من الحيوانات المنوية وتخزينها قبل العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">دواء بوليفي له تأثير بسيط على قدرتك على قيادة أو تدوير أو استخدام أي أدوات أو آلات. إذا كنت تعاني من ردود الفعل المتعلقة بالحقن أو تلف الأعصاب، أو إذا شعرت بالإرهاق أو الضعف أو الدوار (انظر القسم 4)، فلا تقود السيارة أو تستخدم أدوات أو آلات حتى يتوقف ذلك.</p><p dir="RTL">انظر القسم 4 لمزيد من المعلومات حول الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي دواء بوليفي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم (23 ملغ) لكل جرعة، وهذا يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يتم إعطاء دواء بوليفي</strong></p><p dir="RTL">يتم تناول دواء بوليفي تحت إشراف طبيب خبير في إعطاء مثل هذه العلاجات. يُعطى الدواء في الوريد بالتنقيط أكثر من 90 دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كمية دواء بوليفي التي تُعطى</strong></p><p dir="RTL">تعتمد جرعة هذا الدواء على وزن جسمك.</p><ul dir="rtl"><li>جرعة البدء المعتادة هي 1.8 ملغ لكل كيلوغرام من وزن الجسم.</li><li>إذا كنت تعاني من اعتلال الأعصاب المحيطية، فقد يخفض طبيبك الجرعة إلى 1.4 ملغ لكل كيلوغرام من وزن الجسم.</li></ul><p dir="RTL">سيتم إعطاؤك 6 دورات علاجية من دواء بوليفي بالاقتران مع أدويتين أخريين هما ريتوكسيماب وبنداموستين.</p><p dir="RTL">تستمر كل دورة علاجية مدة 21 يومًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول الجرعة</strong></p><p dir="RTL">إذا فاتتك جرعة، يجب تناولها على الفور. لكي يكون العلاج فعالاً بالكامل، من المهم للغاية عدم تفويت جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول دواء بوليفي</strong></p><p dir="RTL">لا تتوقف عن العلاج بدواء بوليفي إلا إذا ناقشت ذلك مع طبيبك. وذلك لأنك إذا وقفت العلاج فقد تسوء حالتك.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، استشر طبيبك أو ممرضتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">من المحتمل أن يسبب دواء بوليفي بعض الآثار الجانبية مثل باقي الأدوية وعلى الرغم من انه لا يصاب بها الجميع. تم الإبلاغ عن الآثار الجانبية التالية مع هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية خطيرة</strong></p><p dir="RTL">استشر طبيبك أو ممرضتك على الفور إذا لاحظت أي من الآثار الجانبية الخطيرة التالية - قد تحتاج إلى علاج طبي عاجل. قد تكون هذه أعراض جديدة أو تغييرًا في الأعراض الحالية.</p><ul dir="rtl"><li>حمى وقشعريرة</li><li>طفح جلدي / شَرَى (مرض طفحي)&rlm;</li><li>التهابات حادة</li><li>الالتهاب الرئوي (التهاب الرئة)</li><li>عدوى الهربس</li><li>عدوى فيروسية</li><li>نزيف غير عادي أو كدمات تحت الجلد</li><li>فقدان الذاكرة، أو صعوبة في التحدث، أو صعوبة في المشي أو مشاكل في الرؤية</li><li>اصفرار الجلد أو بياض العين</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى</strong></p><p dir="RTL">استشر طبيبك أو ممرضتك إذا لاحظت أيًا من الآثار الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار شائعة جدًا </strong>(قد تؤثر على أكثر من شخص من كل 10 أشخاص)</p><ul dir="rtl"><li>حمى أو قشعريرة</li><li>سعال</li><li>قيء</li><li>الالتهاب الرئوي (التهاب الرئة)</li><li>الإسهال أو الإمساك</li><li>الشعور بالغثيان (الغثيان)</li><li>ألم في البطن (البطن)</li><li>الشعور بالتعب (فقر الدم)</li><li>عدم الشعور بالجوع</li><li>الحك</li><li>فقدان الوزن</li><li>ردود الفعل المتعلقة بالحقن</li><li>نزلة برد</li><li>عدوى الهربس</li><li>دوخة</li><li>أحاسيس غير عادية</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار شائعة</strong></p><ul dir="rtl"><li>التهابات حادة</li><li>عدوى فيروسية</li><li>مشاكل في المشي</li><li>التهاب الرئتين</li><li>أنزيمات الكبد المرتفعة</li><li>ألم المفاصل</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا كنت تعاني من أي آثار جانبية، يرجى التحدث إلى طبيبك أو الصيدلي أو ممرضتك. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. عن طريق الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم تخزين دواء بوليفي من قبل المتخصصين في الرعاية الصحية في المستشفى أو العيادة. تفاصيل التخزين هي كما يلي</p><ul dir="rtl"><li>احتفظ بالدواء بعيدًا عن متناول الأطفال.</li><li>لا تستخدم هذا الدواء بعد مرور تاريخ انتهاء الصلاحية الموضح على العبوة. والقارورة بعد انتهاء صلاحيتها. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</li><li>يتم تخزين الدواء في الثلاجة (2 درجة مئوية - 8 درجة مئوية).</li><li>يجب عدم تجمده.</li><li>يتم تخزين الدواء في العلبة الأصلية للحماية من الضوء.</li></ul><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. استشر الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li><strong>المادة الفعالة</strong> هي بولاتوزوماب فيدوتين. تحتوي كل قارورة على 140 ملليغرام (ملغ) بولاتوزوماب فيدوتين. بعد إعادة الحل، كل مليلتر (مل) يحتوي على 20 ملغ بولاتوزوماب فيدوتين.</li></ul><p>&nbsp;</p><ul dir="rtl"><li><strong>المكونات الأخرى</strong> هي: حمض السكسينيك، وهيدروكسيد الصوديوم، وسكروز، وبوليسوربات 20. انظر القسم &quot; يحتوي بوليفي على الصوديوم&quot;.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دواء بوليفي هو مسحوق مُركز لمحلول الحقن الوريدي وهو عبارة عن كتلة بيضاء اللون مائلة إلى اللون الرمادي قليلاً في قارورة زجاجية.</p><p dir="RTL">تتكون كل عبوة من دواء بوليفي من قارورة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إف. هوفمان &ndash; لا روش المحدودة،</p><p dir="RTL">124 جرينزاشيرستراس،</p><p dir="RTL">سي إتش &ndash; 4070 بازل،</p><p dir="RTL">سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ يناير 2020م

للإبلاغ عن الآثار الجانبية:
المملكة العربية السعودية:
-	المركز الوطني للتيقظ والسلامة الدوائية (NPC)
o	فاكس: 966112057662+
o	هاتف: 2038222 - 11 - 966 + داخلي: 2317 – 2356 – 234 
o	مركز اتصالات الهيئة العامة للغذاء والدواء: 19999
o	البريد الإلكتروني: npc.drug@sfda.gov.sa
o	الموقع الإلكتروني: www.sfda.gov.sa/npc 


دول مجلس التعاون الخليجي الأخرى:
-	يرجى الاتصال بالهيئة المختصة ذات الصلة.

مجلس وزراء الصحة العرب

هذا الدواء
-	هذا الدواء منتج يؤثر على صحتك واستهلاكه بطريقة مخالفة للتعليمات يعرض حياتك للخطر.
-	اتبع إرشادات الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي باع لك هذا الدواء.
-	الطبيب والصيدلي هم خبراء في الأدوية وفوائدها ومخاطرها.
-	لا تتوقف من تلقاء نفسك عن العلاج الموصوف لك.
-	لا تكرر نفس الوصفة الطبية من تلقاء نفسك دور استشارة الطبيب.
-	تحفظ جميع الأدوية بعيدا عن متناول الأطفال.

مجلس وزراء الصحة العرب
اتحاد الصيادلة العرب
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Polivy 140 mg powder for concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of powder for concentrate for solution for infusion contains 140 mg of polatuzumab vedotin.

After reconstitution, each mL contains 20 mg of polatuzumab vedotin.

Polatuzumab vedotin is an antibody-drug conjugate composed of the anti-mitotic agent monomethyl auristatin E (MMAE) covalently conjugated to a CD79b directed monoclonal antibody (recombinant humanized immunoglobulin G1 [IgG1], produced in Chinese Hamster Ovary cells by recombinant DNA technology).

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion (powder for concentrate).

White to greyish white lyophilized cake.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polivy must only be administered under the supervision of a healthcare professional experienced in the diagnosis and treatment of cancer patients.</p><p><u>Posology</u></p><p>The recommended dose of Polivy is 1.8&nbsp;mg/kg, given as an intravenous infusion every 21&nbsp;days in combination with bendamustine and rituximab for 6&nbsp;cycles. Polivy, bendamustine and rituximab can be administered in any order on Day&nbsp;1 of each cycle. When administered with Polivy, the recommended dose of bendamustine is 90&nbsp;mg/m<sup>2</sup>/day on Day&nbsp;1 and Day&nbsp;2 of each cycle and the recommended dose of rituximab is 375&nbsp;mg/m<sup>2</sup> on Day&nbsp;1 of each cycle. Due to limited clinical experience in patients treated with 1.8 mg/kg Polivy at a total dose &gt;240 mg, it is recommended not to exceed the dose 240 mg/cycle.</p><p>If not already premedicated, premedication with an antihistamine and anti-pyretic should be administered to patients prior to Polivy.</p><p>&nbsp;</p><p><em>Delayed or missed doses</em></p><p>If a planned dose of Polivy is missed, it should be administered as soon as possible and the schedule of administration should be adjusted to maintain a 21‑day interval between doses.</p><p>&nbsp;</p><p><em>Dose modifications</em></p><p>The infusion rate of Polivy should be slowed or interrupted if the patient develops an infusion-related reaction. Polivy should be discontinued immediately and permanently if the patient experiences a life‑threatening reaction.</p><p>For dose modifications for peripheral neuropathy (section 4.4) see Table 1 below.</p><p>&nbsp;</p><p><strong>Table 1 Polivy dose modifications for peripheral neuropathy (PN)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:922px"><tbody><tr><td style="vertical-align:top; width:226px"><p><strong>Severity of PN on Day 1 of any cycle</strong></p></td><td style="vertical-align:top; width:692px"><p><strong>Dose modification</strong></p></td></tr><tr><td style="vertical-align:top; width:226px"><p>Grade 2-3</p></td><td style="vertical-align:top; width:692px"><p>Withhold Polivy dosing until improvement to &le;&nbsp;Grade 1.</p><p>If recovered to Grade &le;&nbsp;1 on or before Day 14, restart Polivy at a permanently reduced dose of 1.4&nbsp;mg/kg.</p><p>If a prior dose reduction to 1.4&nbsp;mg/kg has occurred, discontinue Polivy.</p><p>If not recovered to Grade &le;&nbsp;1 on or before Day 14, discontinue Polivy.</p></td></tr><tr><td style="vertical-align:top; width:226px"><p>Grade 4</p></td><td style="vertical-align:top; width:692px"><p>Discontinue Polivy.</p></td></tr></tbody></table><p>&nbsp;</p><p>For dose modifications for myelosuppression see Table 2.</p><p><strong>Table 2 Polivy, bendamustine and rituximab dose modifications for myelosuppression&nbsp; </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:1134px"><tbody><tr><td style="vertical-align:top; width:357px"><p><strong>Severity of myelosuppression on Day 1 of any cycle</strong></p></td><td style="vertical-align:top; width:773px"><p><strong>Dose modification<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Grade 3-4 Neutropenia</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top; width:773px"><p>Withhold all treatment until ANC recovers to &gt;&nbsp;1000/&micro;L.</p><p>If ANC recovers to &gt;&nbsp;1000/&micro;L on or before Day&nbsp;7, resume all treatment without any additional dose reductions.</p><p>If ANC recovers to &gt;&nbsp;1000/&micro;L after Day&nbsp;7:</p><p>&middot;&nbsp;&nbsp;&nbsp; restart all treatment with a dose reduction of bendamustine from 90&nbsp;mg/m<sup>2</sup> to 70&nbsp;mg/m<sup>2</sup> or 70&nbsp;mg/m<sup>2</sup> to 50&nbsp;mg/m<sup>2</sup>.</p><p>&middot;&nbsp;&nbsp;&nbsp; if a bendamustine dose reduction to 50&nbsp;mg/m<sup>2</sup> has already occurred, discontinue all treatment.</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Grade 3-4 Thrombocytopenia</p></td><td style="vertical-align:top; width:773px"><p>Withhold all treatment until platelets recover to &gt;75,000/&micro;L.</p><p>If platelets recover to &gt;&nbsp;75,000/&micro;L on or before Day 7, resume all treatment without any dose reductions.</p><p>If platelets recover to &gt;&nbsp;75,000/&micro;L after Day 7:</p><p>&middot;&nbsp;&nbsp;&nbsp; restart all treatment with a dose reduction of bendamustine from 90&nbsp;mg/m<sup>2</sup> to 70&nbsp;mg/m<sup>2</sup> or 70&nbsp;mg/m<sup>2</sup> to 50&nbsp;mg/m<sup>2</sup>.</p><p>&middot;&nbsp;&nbsp;&nbsp; if a bendamustine dose reduction to 50&nbsp;mg/m<sup>2</sup> has already occurred, discontinue all treatment.</p></td></tr></tbody></table><p><sup>1</sup>If primary cause is due to lymphoma, the dose of bendamustine may not need to be reduced.</p><p>&nbsp;</p><p>For dose modifications for Infusion-related reactions see Table 3.</p><p><strong>Table 3: Polivy, bendamustine and rituximab dose modifications for Infusion-related reactions (IRRs)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Severity of IRR on Day 1 of any cycle</strong></p></td><td style="vertical-align:top"><p><strong>Dose modification</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade 1&ndash;3<br />IRR</p></td><td style="vertical-align:top"><p>Interrupt POLIVY infusion and give supportive treatment.</p><p>For the first instance of Grade 3 wheezing, bronchospasm, or generalized urticaria, permanently discontinue Polivy.</p><p>For recurrent Grade 2 wheezing or urticaria, or for recurrence of any Grade 3 symptoms, permanently discontinue Polivy.</p><p>Otherwise, upon complete resolution of symptoms, infusion may be resumed at 50% of the rate achieved prior to interruption. In the absence of infusion-related symptoms, the rate of infusion may be escalated in increments of 50 mg/hour every 30 minutes.</p><p>For the next cycle, infuse Polivy over 90 minutes. If no infusion-related reaction occurs, subsequent infusions may be administered over 30 minutes. Administer premedication for all cycles.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4<br />IRR</p></td><td style="vertical-align:top"><p>Stop Polivy infusion immediately.</p><p>Give supportive treatment.</p><p>Permanently discontinue Polivy.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Elderly </em></p><p>No dose adjustment of Polivy is required in patients &ge;&nbsp;65&nbsp;years of age (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment </em></p><p>No dose adjustment of Polivy is required in patients with creatinine clearance (CrCL)&nbsp;&ge;&nbsp;30&nbsp;mL/min. A recommended dose has not been determined for patients with CrCL&nbsp;&lt;&nbsp;30mL/min due to limited data.</p><p>&nbsp;</p><p><em>Hepatic impairment </em></p><p>The administration of Polivy in patients with moderate or severe hepatic impairment (bilirubin greater than 1.5 &times; upper limit of normal [ULN]) should be avoided.</p><p>No adjustment in the starting dose is required when administering Polivy to patients with mild hepatic impairment (bilirubin greater than ULN to less than or equal to 1.5 &times; ULN or aspartate transaminase [AST] greater than ULN).</p><p>Per studied population in mild hepatic impairment (defined as AST or ALT &gt;1.0 to 2.5 &times; ULN or total bilirubin &gt;1.0 to 1.5 &times; ULN), there was a 40% increase in unconjugated MMAE exposure, which was not deemed clinically significant.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy in children and adolescents less than 18 years have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>Polivy is for intravenous use.</p><p>The initial dose of Polivy should be administered as a 90‑minute intravenous infusion. Patients should be monitored for IRRs/hypersensitivity reactions during the infusion and for at least 90 minutes following completion of the initial dose.</p><p>If the prior infusion was well tolerated, the subsequent dose of Polivy may be administered as a 30‑minute infusion and patients should be monitored during the infusion and for at least 30 minutes after completion of the infusion.</p><p>Polivy must be reconstituted and diluted using aseptic technique under the supervision of a healthcare professional. It should be administered as an intravenous infusion through a dedicated infusion line equipped with a sterile, non-pyrogenic, low-protein binding in-line or add-on filter (0.2 or 0.22&nbsp;micrometer pore size) and catheter. Polivy must not be administered as intravenous push or bolus.</p><p>For&nbsp;instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p><p><em>Precaution to be taken before manipulating or administering the product</em></p><p>Polivy contains a cytotoxic component which is covalently attached to the monoclonal antibody. Follow applicable proper handling and disposal procedure (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Active severe infections (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Myelosuppression</u></p><p>Serious and severe neutropenia and febrile neutropenia have been reported in patients treated with Polivy as early as the first cycle of treatment. Prophylactic granulocyte colony stimulating factor (G‑CSF) administration was required in the clinical development and should be considered. Grade 3 or 4 thrombocytopenia or anaemia can also occur with Polivy. Complete blood counts should be monitored prior to each dose of Polivy. More frequent lab monitoring and/or Polivy delays or discontinuation should be considered for patients with Grade 3 or Grade 4 neutropenia and thrombocytopenia (see section 4.2).</p><p>&nbsp;</p><p><u>Peripheral neuropathy (PN)</u></p><p>PN has been reported in patients treated with Polivy as early as the first cycle of treatment, and the risk increases with sequential doses. Patients with pre-existing PN may experience worsening of this condition. PN reported with treatment with Polivy is predominantly sensory PN. However, motor and sensorimotor PN have also been reported. Patients should be monitored for symptoms of PN such as hypoesthesia, hyperesthesia, paraesthesia, dysesthesia, neuropathic pain, burning sensation, muscle weakness, or gait disturbance. Patients experiencing new or worsening PN may require a delay, dose reduction, or discontinuation of Polivy (see section 4.2).</p><p>&nbsp;</p><p><u>Infections</u></p><p>Serious, life threatening or fatal infections, including opportunistic infections, such as pneumonia (including <em>pneumocystis jirovecii</em> and other fungal pneumonia), bacteraemia, sepsis, herpes infection, and cytomegalovirus infection have been reported in patients treated with Polivy (see section 4.8). Reactivation of latent infections has been reported. Patients should be closely monitored during treatment for signs of bacterial, fungal, or viral infections and seek medical advice if signs and symptoms appear. Anti-infective prophylaxis should be considered throughout treatment with Polivy. Polivy should not be administered in the presence of an active severe infection. Polivy and any concomitant chemotherapy should be discontinued in patients who develop serious infections.</p><p>&nbsp;</p><p><u>Human Immunodeficiency Virus (HIV)</u></p><p>Polivy has not been evaluated in patients with HIV. With regard to co-administration of CYP3A‑inhibitors see section 4.5.</p><p>&nbsp;</p><p><u>Immunization</u></p><p>Live or live-attenuated vaccines should not be given concurrently with the treatment. Studies have not been conducted in patients who recently received live vaccines.</p><p>&nbsp;</p><p><u>Progressive multifocal leukoencephalopathy (PML)</u></p><p>PML has been reported with Polivy treatment (see section 4.8). Patients should be monitored closely for new or worsening neurological, cognitive, or behavioural changes suggestive of PML. Polivy and any concomitant chemotherapy should be withheld if PML is suspected and permanently discontinued if the diagnosis is confirmed.</p><p>&nbsp;</p><p><u>Tumour lysis syndrome (TLS)</u></p><p>Patients with high tumour burden and rapidly proliferative tumour may be at increased risk of TLS. Appropriate measures/prophylaxis in accordance with local guidelines should be taken prior to treatment with Polivy. Patients should be monitored closely for TLS during treatment with Polivy.</p><p>&nbsp;</p><p><u>Infusion-related reactions</u></p><p>Polivy can cause IRRs , including severe cases. Delayed IRRs as late as 24 hours after receiving Polivy have occurred. An antihistamine and antipyretic should be administered prior to the administration of Polivy, and patients should be monitored closely throughout the infusion. If an IRR occurs, the infusion should be interrupted and appropriate medical management should be instituted (see section 4.2).</p><p>&nbsp;</p><p><u>Embryo-foetal toxicity</u></p><p>Based on the mechanism of action and nonclinical studies, Polivy can be harmful to the foetus when administered to a pregnant woman (see section 5.3). Pregnant women should be advised regarding risk to the foetus.</p><p>Women of childbearing potential should be advised to use effective contraception during treatment with Polivy and for at least 9 months after the last dose (see section 4.6). Male patients with female partners of childbearing potential should be advised to use effective contraception during treatment with Polivy and for at least 6 months after the last dose (see section 4.6).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>In non-clinical studies, polatuzumab vedotin has resulted in testicular toxicity, and may impair male reproductive function and fertility (see section 5.3). Therefore, men being treated with Polivy are advised to have sperm samples preserved and stored before treatment (see section 4.6).</p><p>&nbsp;</p><p><u>Elderly</u></p><p>Among 173 patients treated with Polivy in Study GO29365, 95 (55%) were &ge;65 years of age. Patients aged &ge;65 had a numerically higher incidence of serious adverse reactions (64%) than patients aged &lt;65 (53%). Clinical studies of Polivy did not include sufficient numbers of patients aged &ge;65 to determine whether they respond differently from younger patients.</p><p>&nbsp;</p><p><u>Hepatic toxicity</u></p><p>Serious cases of hepatic toxicity that were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, have occurred in patients treated with Polivy (see section 4.8). Pre‑existing liver disease, elevated baseline liver enzymes, and concomitant medicinal products may increase the risk. Liver enzymes and bilirubin level should be monitored.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No dedicated clinical drug-drug interaction studies with polatuzumab vedotin in humans have been conducted.</p><p>&nbsp;</p><p><u>Drug interactions with concomitant medicines that are CYP3A4 inhibitors, substrates or inducers and co-medications that are P-gp inhibitors</u></p><p>Based on physiological-based pharmacokinetic (PBPK) model simulations of MMAE released from polatuzumab vedotin, strong CYP3A4 and P-gp inhibitors (e.g., ketoconazole) may increase the area under the concentration-time curve (AUC) of unconjugated MMAE by 48%. Caution is advised in case of concomitant treatment with CYP3A4 inhibitor. Patients receiving concomitant strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, cobicistat, indinavir, itraconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) should be monitored more closely for signs of toxicities.</p><p>Unconjugated MMAE is not predicted to alter the AUC of concomitant medicines that are CYP3A4 substrates (e.g., midazolam).</p><p>Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenobarbital, phenytoin, St John&rsquo;s wort [<em>Hypericum perforatum</em>]) may decrease the exposure of unconjugated MMAE.</p><p>&nbsp;</p><p><u>Drug interactions of rituximab and bendamustine in combination with polatuzumab vedotin</u></p><p>The pharmacokinetics (PK) of rituximab and bendamustine are not affected by co-administration with polatuzumab vedotin. Concomitant rituximab is associated with increased antibody conjugated MMAE (acMMAE) plasma AUC by 24% and decreased unconjugated MMAE plasma AUC by 37%, based on population PK analysis. No dose adjustment is required.</p><p>Bendamustine does not affect acMMAE and unconjugated MMAE plasma AUC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p><em>Women</em></p><p>Women of childbearing potential should be advised to use effective contraception during treatment with polatuzumab vedotin and for at least 9 months after the last dose.</p><p><em>Men</em></p><p>Male patients with female partners of childbearing potential should be advised to use effective contraception during treatment with polatuzumab vedotin and for at least 6 months after the last dose.</p><p>&nbsp;</p><p><u>Pregnancy </u></p><p>There are no data in pregnant women using Polivy. Studies in animals have shown reproductive toxicity (see section 5.3). Based on the mechanism of action and nonclinical studies, polatuzumab vedotin can be harmful to the foetus when administered to a pregnant woman. In women of childbearing potential, the pregnancy status shall be checked prior to treatment. Polivy is not recommended during pregnancy and in women of childbearing potential not using contraception unless the potential benefit for the mother outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast‑feeding </u></p><p>It is not known whether polatuzumab vedotin or its metabolites are excreted in human breast milk. A risk for breast-feeding children cannot be excluded. Women should discontinue breast-feeding during treatment with Polivy.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>In nonclinical studies, polatuzumab vedotin has resulted in testicular toxicity, and may impair male reproductive function and fertility (see section 5.3).</p><p>Therefore, men being treated with this medicine are advised to have sperm samples preserved and stored before treatment. Men being treated with Polivy are advised not to father a child during treatment and for up to 6 months following the last dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polivy has minor influence on the ability to drive and use machines. IRRs, PN, fatigue, and dizziness may occur during treatment with Polivy (see sections 4.4 and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>For the clinical development program of Polivy as a whole, an estimated total of 588 patients have received Polivy. The adverse drug reactions (ADRs) described in this section were identified during treatment and follow-up of previously treated DLBCL patients from the pivotal clinical trial GO29365. This includes run-in phase patients (n=6) and randomized patients (n=39) who received Polivy in combination with bendamustine and rituximab (BR) compared to randomized patients (n=39) who received BR alone. Randomized patients in the treatment arm received a median of 5 cycles of treatment while randomized patients in the comparator arm received a median of 3 cycles of treatment.</p><p>The most frequently-reported (&ge;&nbsp;30%) ADRs in patients treated with Polivy in combination with BR were anaemia (46.7%), thrombocytopenia (46.7%), neutropenia (46.7%), fatigue (40.0%), diarrhoea (37.8%), nausea (33.3%), and pyrexia (33.3%). Serious adverse reactions were reported in 27% of Polivy plus BR treated patients, which includes febrile neutropenia (6.7%), pyrexia (4.4%), and pneumonia (4.4%).</p><p>ADRs leading to treatment regimen discontinuation in &gt;5% of patients were thrombocytopenia (8.9%) and neutropenia (6.7%).</p><p>&nbsp;</p><p><u>Tabulated list of ADRs from clinical trials</u></p><p>The ADRs are listed below by MedDRA system organ class (SOC) and</p><p>categories of frequency. The corresponding frequency category for each adverse drug reaction is based on the following convention: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1000), very rare (&lt; 1/10,000). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table</strong><strong> 4</strong><strong> Summary of ADRs occurring in relapsed or refractory DLBCL patients treated with Polivy in combination with BR</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:1004px"><tbody><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Very common</p></td><td style="vertical-align:top; width:748px"><p>pneumonia<sup>a</sup>, herpes virus infection<sup>a</sup>, upper respiratory tract infection</p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Common</p></td><td style="vertical-align:top; width:748px"><p>sepsis, cytomegalovirus infection</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Very common</p></td><td style="vertical-align:top; width:748px"><p>febrile neutropenia, neutropenia, thrombocytopenia, anaemia, leukopenia, lymphopenia</p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Common</p></td><td style="vertical-align:top; width:748px"><p>pancytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Very common</p></td><td style="vertical-align:top; width:748px"><p>hypokalaemia, hypocalcaemia, hypoalbuminemia, decreased appetite</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Very common</p></td><td style="vertical-align:top; width:748px"><p>neuropathy peripheral, peripheral sensory neuropathy, dizziness</p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Common</p></td><td style="vertical-align:top; width:748px"><p>gait disturbance, paraesthesia, hypoaesthesia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Common</p></td><td style="vertical-align:top; width:748px"><p>vision blurred</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Very common</p></td><td style="vertical-align:top; width:748px"><p>cough</p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Common</p></td><td style="vertical-align:top; width:748px"><p>pneumonitis</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Very common</p></td><td style="vertical-align:top; width:748px"><p>diarrhoea, nausea, constipation, vomiting, abdominal pain, upper abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Very common</p></td><td style="vertical-align:top; width:748px"><p>pruritis</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>Musculoskeletal disorders</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Common</p></td><td style="vertical-align:top; width:748px"><p>arthralgia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Very common</p></td><td style="vertical-align:top; width:748px"><p>fatigue, pyrexia, asthenia, chills</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Very common</p></td><td style="vertical-align:top; width:748px"><p>weight decreased</p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Common</p></td><td style="vertical-align:top; width:748px"><p>transaminase elevation, lipase increase, hypophosphataemia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1001px"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top; width:255px"><p>Very Common</p></td><td style="vertical-align:top; width:748px"><p>infusion-related reactions<sup>b</sup></p></td></tr></tbody></table><p><sup>a </sup>ADR associated with fatal outcome</p><p><sup>b</sup> Defined as all adverse reactions reported as related to study treatment within 24 hours after treatment infusion</p><p>Uncommon, rare and very rare ADRs: none</p><p>&nbsp;</p><p><u>Description of selected adverse drug reactions </u></p><p>In the Polivy plus BR arm, Grade 3 or higher neutropenia, thrombocytopenia, and anaemia were reported in 40%, 37.8%, and 24.4% of patients, respectively.</p><p>&nbsp;</p><p><em>Myelosuppression</em></p><p>8.9% of patients in the Polivy plus BR arm discontinued Polivy due to neutropenia compared to 2.6% of patients in the BR arm who discontinued treatment due to neutropenia. Thrombocytopenia events led to discontinuation of treatment in 11.1% of patients in the Polivy plus BR arm and 5.1% of patients in the BR arm. No patients discontinued treatment due to anaemia in either the Polivy plus BR arm or BR arm.</p><p>&nbsp;</p><p><em>Peripheral neuropathy (PN)</em></p><p>In the Polivy plus BR arm, Grade 1 PN and Grade 2 PN were reported in 26.7% and 13.3% of patients, respectively. In the BR arm, Grade 1 and 2 PN events were reported in 2.6% and 5.1% of patients, respectively. No Grade 3-5 PN events were reported in either the Polivy plus BR arm or BR arm. 2.2%&nbsp;of patients discontinued Polivy treatment due to PN and 4.4% of patients had Polivy dose reduction due to PN. No patients in the BR arm discontinued treatment or had dose reductions due to PN. In the Polivy plus BR arm, the median onset to first event of PN was 1.8 months, and 61.1% of patients with PN events reported event resolution.</p><p>&nbsp;</p><p><em>Infections</em></p><p>Infections, including pneumonia and other types of infections, were reported in 53.3% of patients in the Polivy plus BR arm and 51.3% of patients in the BR arm. In the Polivy plus BR arm, serious infections were reported in 28.9% of patients and fatal infections were reported in 8.9% of patients. In the BR arm, serious infections were reported in 30.8% of patients and fatal infections were reported in 10.3% of patients. One patient (2.2%) in the Polivy plus BR arm discontinued treatment due to infection compared to 5.1% of patients in the BR arm.</p><p>&nbsp;</p><p><em>Progressive multifocal leukoencephalopathy (PML)</em></p><p>One case of PML, which was fatal, occurred in one patient treated with Polivy plus bendamustine and obinutuzumab. This patient had three prior lines of therapy that included anti-CD20 antibodies.</p><p>&nbsp;</p><p><em>Hepatic toxicity</em></p><p>In another study, two cases of serious hepatic toxicity (hepatocellular injury and hepatic steatosis) were reported and were reversible.</p><p>&nbsp;</p><p><em>Gastrointestinal toxicity</em></p><p>Gastrointestinal toxicity events were reported in 80.0% of patients in the Polivy plus BR arm compared to 64.1% of patients in the BR arm. Most events were Grade 1-2, and Grade 3-4 events were reported in 22.2% of patients in the Polivy plus BR arm compared to 12.8% of patients in the BR arm. The most common gastrointestinal toxicity events were diarrhoea and nausea.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:411.75pt;height:27.15pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><img alt="" width="956" height="395" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with overdose in human clinical trials. The highest dose tested to date is 2.4&nbsp;mg/kg administered as an intravenous infusion; it was associated with a higher frequency and severity of PN events. Patients who experience overdose should have immediate interruption of their infusion and be closely monitored.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antineoplastic agents; other antineoplastic agents; monoclonal antibodies ATC code: L01XC37.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Polatuzumab vedotin is a CD79b‑targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl auristatin E, or MMAE) to B‑cells, which results in the killing of malignant B-cells. The polatuzumab vedotin molecule consists of MMAE covalently attached to a humanized immunoglobulin G1 monoclonal antibody via a cleavable linker. The monoclonal antibody binds with high affinity and selectivity to CD79b, a cell surface component of the B-cell receptor.</p><p>CD79b expression is restricted to normal cells within the B‑cell lineage (with the exception of plasma cells) and malignant B-cells; it is expressed in &gt;&nbsp;95% of diffuse large B‑cell lymphoma. Upon binding CD79b, polatuzumab vedotin is rapidly internalized and the linker is cleaved by lysosomal proteases to enable intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><em>Cardiac electrophysiology </em></p><p>Polatuzumab vedotin did not prolong the mean QTc interval to any clinically relevant extent based on ECG data from two open-label studies in&nbsp;patients with previously treated B-cell malignancies at the recommended dosage.&nbsp;</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>The efficacy of Polivy was evaluated in an international, multicentre, open-label study (GO29365) which included a randomized cohort of 80 patients with previously treated DLBCL. Patients were randomized 1:1 to receive Polivy plus BR or BR alone for six 21-day cycles. Patients were stratified by duration of response to last prior treatment of &le;&nbsp;12 months or &gt;&nbsp;12 months.</p><p>Eligible patients were not candidates for autologous haematopoietic stem cell transplant (HSCT) and had relapsed or refractory disease after receiving at least one prior systemic chemotherapy regimen. The study excluded patients with prior allogeneic HSCT, central nervous system lymphoma, transformed indolent lymphoma, grade 3b FL, significant cardiovascular or pulmonary disease, active infections, AST or alanine transaminase (ALT) &gt;2.5&acute; ULN or total bilirubin &ge;1.5 x ULN, creatinine &gt;1.5 x ULN (or CrCl&nbsp; &lt;40&nbsp;mL/min) unless due to underlying lymphoma.</p><p>Polivy was given intravenously at 1.8&nbsp;mg/kg administered on Day&nbsp;2 of Cycle&nbsp;1 and on Day&nbsp;1 of Cycles 2‑6. Bendamustine was administered at 90&nbsp;mg/m<sup>2 </sup>intravenously daily on Days&nbsp;2 and 3 of Cycle&nbsp;1 and on Days&nbsp;1 and 2 of Cycles 2‑6. Rituximab was administered at 375&nbsp;mg/m<sup>2</sup> on Day&nbsp;1 of Cycles&nbsp;1‑6.</p><p>Among the 80 patients who were randomized to receive Polivy plus BR (n=40) or BR alone (n&nbsp;=&nbsp;40) the majority were white (71%) and male (66%). The median age was 69 years (range:&nbsp;30‑86 years). Sixty-four out of 80 patients (80%) had ECOG performance score (PS) of 0‑1 and 14 out of 80 patients (18%) had ECOG PS of 2. The majority of patients (98%) had DLBCL not otherwise specified (NOS). Overall, 48% of patients had activated B-cell (ABC) DLBCL and 40% had germinal center B-cell like (GCB) DLBCL. Primary reasons patients were not candidates for HSCT included age (40%), insufficient response to salvage therapy (26%) and prior transplant failure (20%). The median number of prior therapies was 2 (range:&nbsp;1‑7), with 29% (n&nbsp;=&nbsp;23) receiving one prior therapy, 25% (n&nbsp;=&nbsp;20) receiving 2 prior therapies, and 46% (n&nbsp;=&nbsp;37) receiving 3 or more prior therapies. All except one patient in the pola+BR arm of the randomized Phase II were na&iuml;ve to bendamustine treatment. 80% of patients had refractory disease.</p><p>The primary endpoint of the study was complete response (CR) rate at end of treatment (6-8 weeks after Day&nbsp;1 of Cycle&nbsp;6 or last study treatment) as assessed by PET-CT by an Independent Review Committee (IRC).</p><p><img alt="" width="783" height="797" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&nbsp;</p><p>Overall survival (OS) was an exploratory endpoint which was not type 1 error controlled. The median OS in the Polivy+BR arm was 12.4 months (95% CI: 9.0, NE) vs 4.7 months (95% CI: 3.7, 8.3) in the control arm. The unadjusted estimate for OS HR was 0.42. When accounting for the influence of baseline covariates&nbsp;the OS HR was adjusted to 0.59.&nbsp;Covariates included&nbsp;primary refractory status, number of prior lines of therapy, IPI, and prior stem cell transplant.</p><p>Investigator-assessed progression free survival (PFS) was an exploratory endpoint which was not type 1 error controlled. The median PFS in the Polivy+BR arm was 7.6 months (95% CI: 6.0, 17.0) vs 2.0 months (95% CI: 1.5, 3.7) in the control arm. The unadjusted estimate for PFS HR was 0.34.</p><p>&nbsp;</p><p><u>Immunogenicity </u></p><p>As with all therapeutic proteins, there is the potential for an immune response in patients treated with polatuzumab vedotin. Across all arms of study GO29365, 8 out of 134 (6.0%) patients tested positive for anti-polatuzumab vedotin antibodies at one or more post-baseline time points. Across seven clinical studies, 14 out of 536 (2.6%) patients tested positive for anti-polatuzumab vedotin antibodies at one or more post-baseline time points. Due to the limited number of anti-polatuzumab vedotin antibody positive patients, no conclusions can be drawn concerning a potential effect of immunogenicity on efficacy or safety.</p><p>Immunogenicity assay results are highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications and underlying disease. For these reasons, comparison of incidence of antibodies to polatuzumab vedotin with the incidence of antibodies to other products may be misleading.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit results of studies with Polivy in all subsets of the paediatric population for the treatment of mature B-cell neoplasms (see section 4.2 for information on paediatric use). This medicinal product has been authorised under a so-called &lsquo;conditional approval&rsquo; scheme. This means that further evidence on this medicinal product is awaited.</p><p>The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antibody-conjugated MMAE (acMMAE) plasma exposure increased dose-proportionally over the 0.1 to 2.4&nbsp;mg/kg polatuzumab vedotin dose range. After the first 1.8 mg/kg polatuzumab vedotin dose, the acMMAE mean maximum concentration (C<sub>max</sub>) was 803 (&plusmn; 233) ng/mL and the area under the concentration-time curve from time zero to infinity (AUC<sub>inf</sub>) was 1860 (&plusmn;966) day&bull;ng/mL. Based on the population PK analysis, Cycle&nbsp;3 acMMAE AUC increased by approximately 30% over Cycle&nbsp;1 AUC, and achieved more than 90% of the Cycle&nbsp;6 AUC. The terminal half-life at Cycle&nbsp;6 was approximately 12 days (95% CI of 8.1‑19.5&nbsp;days) for acMMAE. Based on population PK analysis, the predicted acMMAE concentration at the end of cycle 6 is approximately 80% of the theoretical steady-state value. Exposures of unconjugated MMAE, the cytotoxic component of polatuzumab vedotin, increased dose proportionally over the 0.1 to 2.4&nbsp;mg/kg polatuzumab vedotin dose range. MMAE plasma concentrations followed formation rate limited kinetics. After the first 1.8&nbsp;mg/kg polatuzumab vedotin dose, the C<sub>max</sub> was 6.82 (&plusmn; 4.73)&nbsp;ng/mL, the time to maximum plasma concentration is approximately 2.5 days, and the terminal half-life is approximately 4 days. Plasma exposures of unconjugated MMAE are &lt;&nbsp;3% of acMMAE exposures. Based on the population PK analysis there is a decrease of plasma unconjugated MMAE exposure (AUC) after repeated every-three-week dosing.</p><p>Based on population pharmacokinetics simulations, a sensitivity analysis predicted exposure to unconjugated MMAE for patients with bodyweight over 100 kg to be increased by 27%.</p><p><u>Absorption </u></p><p>Polivy is administered as an intravenous infusion. There have been no studies performed with other routes of administration.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The population estimate of central volume of distribution for acMMAE was 3.15&nbsp;L, which approximated plasma volume<strong>. </strong><em>In vitro</em>, MMAE is moderately bound (71%‑77%) to human plasma&nbsp;</p><p>proteins. MMAE does not significantly partition into human red blood cells <em>in</em> <em>vitro</em>; the blood to plasma ratio is 0.79 to 0.98.</p><p><em>In vitro</em> data indicate that MMAE is a P-gp substrate but does not inhibit P-gp at clinically relevant concentrations.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Polatuzumab vedotin is expected to undergo catabolism in patients, resulting in the production of small peptides, amino acids, unconjugated MMAE, and unconjugated MMAE related catabolites. The levels of MMAE metabolites have not been measured in human plasma.</p><p><em>In vitro</em> studies indicate that MMAE is a substrate for CYP3A4/5 but does not induce major CYP enzymes. MMAE is a weak time-dependent inhibitor of CYP3A4/5 but does not competitively inhibit CYP3A4/5 at clinically relevant concentrations.</p><p>MMAE does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Based on a population PK analysis, the conjugate (acMMAE) is primarily eliminated by non-specific linear clearance pathway with a value of 0.9&nbsp;L/day. <em>In vivo </em>studies in rats dosed with polatuzumab vedotin (radiolabel on MMAE) demonstrate that the majority of radioactivity is excreted in faeces and the minority of radioactivity is excreted in urine.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>No studies have been conducted to investigate the pharmacokinetics of polatuzumab vedotin in the paediatric population (&lt;18 years old).</p><p>&nbsp;</p><p><u>Elderly</u></p><p>Age did not have an effect on the pharmacokinetics of acMMAE and unconjugated MMAE based on a population PK analysis with patients aged 20‑89&nbsp;years. No significant difference was observed in the pharmacokinetics of acMMAE and unconjugated MMAE among patients &lt;&nbsp;65 years of age (n&nbsp;=&nbsp;187) and patients &ge;&nbsp;65 years of age (n&nbsp;=&nbsp;273).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>In patients with mild (CrCL 60‑89&nbsp;mL/min, n&nbsp;=&nbsp;161) or moderate (CrCL 30‑ 59&nbsp;mL/min, n&nbsp;=&nbsp;109) renal impairment, acMMAE and unconjugated MMAE exposures are similar to patients with normal renal function (CrCL &ge;&nbsp;90 mL/min, n&nbsp;=&nbsp;185), based on a population PK analysis. There are insufficient data to assess the impact of severe renal impairment (CrCL 15‑29&nbsp;mL/min, n&nbsp;=&nbsp;3) on PK. No data are available in patients with end-stage renal disease and/or who are on dialysis.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>In patients with mild hepatic impairment [AST or ALT &gt;1.0 to 2.5 &times; ULN or total bilirubin &gt;1.0 to 1.5&nbsp;&times; ULN], n&nbsp;=&nbsp;54], acMMAE exposures are similar whereas unconjugated MMAE AUC are 40% higher compared to patients with normal hepatic function (n&nbsp;=&nbsp;399), based on a population PK analysis.</p><p>There are insufficient data to assess the impact of moderate hepatic impairment (total bilirubin&nbsp;&gt;&nbsp;1.5‑3&times;ULN, n&nbsp;=&nbsp;2) on PK. No data are available in patients with severe hepatic impairment or liver transplantation.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Systemic toxicity</p><p>In both rats and cynomolgus monkeys, the predominant systemic toxicities associated with administration of MMAE and polatuzumab vedotin included reversible bone marrow toxicity and associated peripheral blood cell effects.</p><p>&nbsp;</p><p>Genotoxicity</p><p>No dedicated mutagenicity studies have been performed with polatuzumab vedotin. MMAE was not mutagenic in the bacterial reverse mutation assay (Ames test) or the L5178Y mouse lymphoma forward mutation assay.</p><p>MMAE was genotoxic in the rat bone marrow micronucleus study probably through an aneugenic mechanism. This mechanism is consistent with the pharmacological effect of MMAE as a microtubule disrupting agent.</p><p>&nbsp;</p><p>Carcinogenicity</p><p>No dedicated carcinogenicity studies have been performed with polatuzumab vedotin and/or MMAE.</p><p>&nbsp;</p><p>Impairment of fertility</p><p>No dedicated fertility studies in animals have been performed with polatuzumab vedotin. However, results of the 4-week rat toxicity study indicate the potential for polatuzumab vedotin to impair male reproductive function and fertility. Testicular seminiferous tubule degeneration&nbsp;did not reverse following a 6-week treatment-free period and correlated with decreased testes weight and gross findings at recovery necropsy of small and/or soft testes in males given&nbsp;&sup3;&nbsp;2&nbsp;mg/kg.</p><p>&nbsp;</p><p>Reproductive toxicity</p><p>No dedicated teratogenicity studies in animals have been performed with polatuzumab vedotin. However, treatment of pregnant rats with MMAE at 0.2&nbsp;mg/kg caused embryolethality and foetal malformations (including protruding tongue, malrotated limbs, gastroschisis, and agnathia). Systemic exposure (AUC) in rats at a dose of 0.2&nbsp;mg/kg MMAE is approximately 50% of the AUC in patients who received the recommended dose of 1.8&nbsp;mg/kg Polivy every 21-days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Succinic acid</p><p>Sodium hydroxide (for pH-adjustment)</p><p>Sucrose</p><p>Polysorbate 20 (E 432)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed or diluted with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
2 years 

Reconstituted solution 
From a microbiological point of view, the reconstituted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours refrigerated (2 °C - 8 °C), unless reconstitution has taken place in controlled and validated aseptic conditions. Chemical and physical in-use stability of the reconstituted solution has been demonstrated for up to 72 hours refrigerated (2 °C - 8 °C) and up to 24 hours at room temperature (9 °C - 25 °C). 

Diluted solution 
From a microbiological point of view, the prepared solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours refrigerated (2 °C - 8 °C), unless dilution has taken place in controlled and validated aseptic conditions. Chemical and physical stability of the prepared solution for infusion has been demonstrated for the durations listed in Table 6. The diluted solution must be discarded if storage time exceeds the limits specified in Table 6. 

Table 6 		Durations for which chemical and physical stability of the prepared solution for infusion have been demonstrated

Diluent used to prepare solution for infusion	Solution for infusion 
                                                                                         storage conditions1
Sodium chloride 9 mg/mL (0.9%) 	                        Up to 24 hours refrigerated (2 °C - 8 °C) or
                                                                                        up to 4 hours at room temperature (9 °C - 25 °C) 
Sodium chloride 4.5 mg/mL (0.45%)                 	Up to 72 hours refrigerated (2 °C - 8 °C) or
                                                                                        up to 8 hours at room temperature (9 °C - 25 °C)
5% Glucose 	                                                                Up to 72 hours refrigerated (2 °C - 8 °C) or
                                                                                        up to 8 hours at room temperature (9 °C - 25 °C)

1 To ensure product stability, do not exceed specified storage durations.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C - 8&nbsp;&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20&nbsp;mL vial (colourless Type 1 glass) closed with a stopper (fluororesin laminate), with an aluminum seal with plastic flip-off cap containing 140&nbsp;mg polatuzumab vedotin. Pack size of one vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General precautions</u></p><p>Polivy contains a cytotoxic component. To be administered under the supervision of a physician experienced in the use of cytotoxic agents. Procedures for proper handling and disposal of antineoplastic and cytotoxic medicines should be used.</p><p>The reconstituted product contains no preservative and is intended for single-dose only. Proper aseptic technique throughout the handling of this medicinal product should be followed.</p><p>Polivy must be reconstituted using sterile water for injection and diluted into an intravenous infusion bag containing sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection, or sodium chloride 4.5&nbsp;mg/ml (0.45%) solution for injection, or 5% glucose prior to administration.</p><p>The reconstituted solution and solution for infusion should not be frozen or exposed to direct sunlight.</p><p>&nbsp;</p><p><u>Instructions for reconstitution</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Using a sterile syringe, slowly inject 7.2&nbsp;mL of sterile water for injection into the 140&nbsp;mg Polivy vial to yield a single-dose solution containing 20&nbsp;mg/mL polatuzumab vedotin. Direct the stream toward the wall of the vial and not directly on the lyophilized cake.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swirl the vial gently until completely dissolved. Do not shake.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inspect the reconstituted solution for discoloration and particulate matter. The reconstituted solution should appear colourless to slightly brown, clear to slightly opalescent, and free of visible particulates. Do not use if the reconstituted solution is discoloured, is cloudy, or contains visible particulates.</p><p>&nbsp;</p><p><u>Instructions for dilution</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Polivy must be diluted to a final concentration of 0.72‑2.7&nbsp;mg/mL in an intravenous infusion bag, with a minimum volume of 50&nbsp;mL, containing 9 mg/mL sodium chloride solution for injection, or 4.5&nbsp;mg/mL sodium chloride solution for injection, or 5% glucose.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Determine the volume of 20&nbsp;mg/mL reconstituted solution needed based on the required dose (see below):</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>Total Polivy dose (mL) to be further diluted =</p></td><td style="vertical-align:top"><p><u>Polivy dose (mg/kg) X patient&rsquo;s weight (kg)</u></p></td></tr><tr><td style="vertical-align:top"><p>Reconstituted vial concentration (20&nbsp;mg/mL)</p></td></tr></tbody></table><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the required volume of reconstituted solution from the Polivy vial using a sterile syringe and dilute into the intravenous infusion bag. Discard any unused portion left in the vial.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently mix the intravenous bag by slowly inverting the bag. Do not shake.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inspect the intravenous bag for particulates and discard if present.</p><p>&nbsp;</p><p>Avoid transportation of the prepared solution for infusion as agitation stress can result in aggregation. If the prepared infusion will be transported, remove air from the infusion bag and limit transportation to 30 minutes room temperature (9&deg;C&nbsp;-&nbsp;25&deg;C) or 24 hours refrigerated (2&deg;C&nbsp;-&nbsp;8&deg;C). If air is removed, an infusion set with a vented spike is required to ensure accurate dosing during the infusion. The total storage plus transportation times of the diluted product should not exceed the storage duration specified in Table 6 (see section 6.3).</p><p>Polivy must be administered using a dedicated infusion line equipped with sterile, non-pyrogenic, low‑protein binding in-line or add-on filter (0.2 or 0.22 micrometer pore size) and catheter.</p><p>Polivy is compatible with intravenous infusion bags with product contacting materials of polyvinyl chloride (PVC) or polyolefins such as polyethylene (PE) and polypropylene. In addition, no incompatibilities have been observed with infusion sets or infusion aids with product contacting materials of PVC, PE, polyurethane, polybutadiene, acrylonitrile butadiene styrene, polycarbonate, polyetherurethane, fluorinated ethylene propylene, or polytetrafluorethylene and with filter membranes composed of polyether sulfone or polysulfone.</p><p>&nbsp;</p><p><u>Disposal </u></p><p>Polivy is for single-use only.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                F. Hoffmann-La Roche Ltd, 
Grenzacherstrasse 124
CH-4070 Basel
Switzerland.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                16 January 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>